Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M802 in HER2-Positive Advanced Solid Tumors
NCT04501770Phase 1Completed
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Sep 2018
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of M802 in HER2-positive solid tumor, sponsored by Wuhan YZY Biopharma Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose up to 1 year. Started Sep 2018; status: completed.
02
Drugs
M802
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT04501770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501770.